These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12921516)

  • 1. Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.
    Schatz RA
    Ann Pharmacother; 2003 Sep; 37(9):1321-4. PubMed ID: 12921516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
    Street JS; Clark WS; Gannon KS; Cummings JL; Bymaster FP; Tamura RN; Mitan SJ; Kadam DL; Sanger TM; Feldman PD; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2000 Oct; 57(10):968-76. PubMed ID: 11015815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.
    Reeves RR; Torres RA
    South Med J; 2003 Jul; 96(7):699-701. PubMed ID: 12940325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.
    Wolfgang SA
    Am J Health Syst Pharm; 1999 Nov; 56(21):2245-6. PubMed ID: 10565707
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of olanzapine for elderly patients with psychotic disorders: a review.
    Madhusoodanan S; Sinha S; Brenner R; Gupta S; Bogunovic O
    Ann Clin Psychiatry; 2001 Dec; 13(4):201-13. PubMed ID: 11958362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
    Street JS; Clark WS; Kadam DL; Mitan SJ; Juliar BE; Feldman PD; Breier A
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S62-70. PubMed ID: 11748789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.
    Marsh L; Lyketsos C; Reich SG
    Psychosomatics; 2001; 42(6):477-81. PubMed ID: 11815682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine and the new generation of antipsychotic agents: patterns of use.
    Glazer WM
    J Clin Psychiatry; 1997; 58 Suppl 10():18-21. PubMed ID: 9265912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine and negative symptoms.
    Rosen EH
    J Clin Psychiatry; 1998 Oct; 59(10):537-8. PubMed ID: 9818636
    [No Abstract]   [Full Text] [Related]  

  • 10. An open trial of olanzapine in the treatment of patients with psychotic depression.
    Nelson EB; Rielage E; Welge JA; Keck PE
    Ann Clin Psychiatry; 2001 Sep; 13(3):147-51. PubMed ID: 11791952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of psychogeriatric patient.
    Zannino G; Gargiulo A; Lamenza F; Marotta MG; Barzotti T; Silvestri A; Ettorre E; Marigliano V
    Arch Gerontol Geriatr Suppl; 2004; (9):465-70. PubMed ID: 15207448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of high-dose olanzapine in refractory psychosis.
    Reich J
    Am J Psychiatry; 1999 Apr; 156(4):661. PubMed ID: 10200755
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine.
    Weintraub E; Robinson C
    Ann Clin Psychiatry; 2000 Dec; 12(4):247-9. PubMed ID: 11140927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
    Schneider LS; Tariot PN; Lyketsos CG; Dagerman KS; Davis KL; Davis S; Hsiao JK; Jeste DV; Katz IR; Olin JT; Pollock BG; Rabins PV; Rosenheck RA; Small GW; Lebowitz B; Lieberman JA
    Am J Geriatr Psychiatry; 2001; 9(4):346-60. PubMed ID: 11739062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label olanzapine treatment in five preadolescent children.
    Krishnamoorthy J; King BH
    J Child Adolesc Psychopharmacol; 1998; 8(2):107-13. PubMed ID: 9730076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.
    Moretti R; Torre P; Antonello RM; Cazzato G; Griggio S; Bava A
    Am J Alzheimers Dis Other Demen; 2003; 18(4):205-14. PubMed ID: 12955785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis.
    Fawcett RG
    J Clin Psychiatry; 2002 Feb; 63(2):169. PubMed ID: 11874224
    [No Abstract]   [Full Text] [Related]  

  • 19. Olanzapine: a new typical antipsychotic drug.
    Meltzer HY; Fibiger HC
    Neuropsychopharmacology; 1996 Feb; 14(2):83-5. PubMed ID: 8822530
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of olanzapine in hereditary coproporphyria.
    Strauss J; DiMartini A
    Psychosomatics; 1999; 40(5):444-5. PubMed ID: 10479951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.